Cartesian Therapeutics (RNAC) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 0.1.
- Cartesian Therapeutics' Equity Ratio fell 592346.25% to 0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1, marking a year-over-year decrease of 592346.25%. This contributed to the annual value of 0.02 for FY2024, which is 9891.64% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Equity Ratio stood at 0.1, which was down 592346.25% from 0.01 recorded in Q2 2025.
- Cartesian Therapeutics' Equity Ratio's 5-year high stood at 0.57 during Q3 2023, with a 5-year trough of 1.44 in Q4 2023.
- Its 5-year average for Equity Ratio is 0.06, with a median of 0.01 in 2025.
- Per our database at Business Quant, Cartesian Therapeutics' Equity Ratio soared by 213720.2% in 2022 and then tumbled by 592346.25% in 2025.
- Cartesian Therapeutics' Equity Ratio (Quarter) stood at 0.14 in 2021, then surged by 301.55% to 0.57 in 2022, then tumbled by 355.12% to 1.44 in 2023, then surged by 98.92% to 0.02 in 2024, then plummeted by 515.12% to 0.1 in 2025.
- Its Equity Ratio stands at 0.1 for Q3 2025, versus 0.01 for Q2 2025 and 0.05 for Q1 2025.